33. Kwon M, Bautista G, Balsalobre P, et al. Haplo-cord transplantation using CD34þ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Transfusion-related alloimmunization is a potent barrier to the engraftment of allogeneic hematopoietic stem cells in patients with nonmalignant diseases (NMDs). Memory T cells, which drive alloimmunization, are relatively resistant to commonly used conditioning agents. Alefacept, a recombinant leukocyte function antigen-3/ IgG1 fusion protein, targets CD2 and selectively depletes memory versus naive T cells. Three multiply transfused pediatric patients with NMD received a short course of high-dose i.v. alefacept (.25 mg/kg/dose on days À40 and À9 and .5 mg/kg/dose on days À33, À26, À19, and À12) before undergoing unrelated allogeneic transplant in the setting of reduced-intensity pretransplant conditioning and calcineurin inhibitorebased post-transplant graft-versus-host disease (GVHD) prophylaxis. Alefacept infusions were well tolerated in all patients. Peripheral blood flow cytometry was performed at baseline and during and after alefacept treatment. 
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many pediatric patients with life-threatening nonmalignant diseases (NMDs) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Rejection remains an impediment to successful transplantation in many of these disorders, especially in the setting of alternative donor graft combined with reduced-intensity conditioning [15] [16] [17] [18] . Because most of these patients require multiple erythrocyte and/or platelet transfusions as part of their routine medical care before HSCT, transfusion-related alloimmunization to minor and major histocompatibility antigens likely accounts for part of their risk for graft rejection [19] [20] [21] [22] [23] . Biologically, memory T cells have been shown to underlie this sensitization to donor antigens and to drive graft rejection [22] [23] [24] . Natural killer (NK) cells have also been shown to induce potent transplant rejection in murine models and patients [25] [26] [27] , especially in the setting of limiting stem cell doses, with the NK cell immunoglobulin-like receptor ligand group correlating with risk of rejection [28, 29] .
Alefacept (Amevive; Astellas, Inc., Northbrook, IL, USA) is a recombinant leukocyte function antigen-3 (LFA-3)/IgG1 fusion protein that targets CD2, thereby depleting CD2-expressing cells via antibody-dependent cellular cytotoxicity (ADCC) [30] [31] [32] [33] [34] [35] [36] . Alefacept is well tolerated and has been previously demonstrated to produce a gradual and dose-dependent reduction in memory T cells (that highly express CD2), which plateaus 5 to 6 weeks after drug administration [36] . The phase III study of alefacept in psoriasis used a mid-range dose of 7.5 mg (.15 mg/kg for a 50-kg adult) weekly for 12 weeks. The mid-range dosing strategy was chosen for psoriasis patients due to concerns regarding the potential infectious risks associated with the more significant CD4 depletion that occurred with higher doses, and this was the dose ultimately approved by the US Food and Drug Administration in 2003. Given the link between memory T cellemediated alloimmunization and HSCT rejection and the ability of alefacept to selectively deplete these cells, we hypothesized that alefacept administration before the start of conditioning might safely and effectively counter the risk of rejection in multiply transfused patients with NMDs. Based on the dose-dependent reduction in memory T cells demonstrated in the dosefinding study in psoriasis [36] , we additionally reasoned that dose escalation beyond the highest dose in the previous trials might maximize the benefit of alefacept preconditioning in a patient population in which posttransplant reconstitution with donor T cells would mitigate any long-term risks of alefacept-induced T cell depletion.
To begin to test these hypotheses, we launched a pilot study of alefacept given at a dose of .5 mg/kg/dose weekly for 5 weeks during transplant preconditioning in multiply transfused children receiving reduced-intensity conditioning and unrelated donor transplant for nonmalignant hematologic disorders. Herein we report our results, both clinical and mechanistic, in the first 3 patients we enrolled on this study. Unfortunately, the manufacturer terminated production of alefacept for fiscal reasons during the conduct of this study, thus prompting premature interruption of the trial. Results in the first 3 patients demonstrate that full donor engraftment was achieved in all cases, and flow cytometry demonstrated depletion of both memory T cells and NK cells during alefacept treatment. These results suggest biologic activity of alefacept in pediatric HSCT patients and argue for renewed development of CD2-targeted agents for HSCT patients at high risk of transplant rejection.
METHODS

Study Design and Patients
This was a single-arm pilot study with an accrual goal of 5 patients. Patients were enrolled at the Aflac Cancer and Blood Disorders Center within Children's Healthcare of Atlanta (CHOA). The trial was registered at clinicaltrials.gov (NCT01319851) and approved by the Institutional Review Board at CHOA and Emory University. Investigational New Drug exemption was obtained for the administration of alefacept. Eligibility criteria included signed informed consent, age 0 to 21 years, NMD requiring at least 5 transfusions (platelet, erythrocyte, or granulocyte units), adequate organ function, !7/8 matched related or unrelated bone marrow donor (HLA-A, -B, -C, and -DR; antigen or allele mismatch was permitted) or !5/6 cord blood unit (HLA-A, -B, and -DRB1; allele mismatch permitted except at -DRB1) with a recommended dose of 5 Â 10 7 total nucleated cells (TNCs)/kg recipient weight, and an HLA antibody screen negative for disparate HLA molecules (in patients with partially HLA-matched allografts). The study was closed to accrual in 2012 after Astellas discontinued production of alefacept and the drug became unavailable.
Treatment Protocol
Alefacept preconditioning All patients received alefacept .5 mg/kg/dose i.v., with the first dose split on days À40 and À39 and the remaining doses given on days À33, À26, À19, and À12 (eg, weekly for 5 doses). Alefacept was diluted in sterile water (2 mL total volume) and administered via i.v. push followed by a normal saline flush per the package insert. * Approximate, before transplantation. y All regimen-related toxicities were determined to be unlikely attributable to the study drug. z Infections were determined to be possibly attributable to the study drug.
x aGVHD of the skin and gut, diagnosed on day þ27, maximal grade III. k Pulmonary aspergillosus by computed tomography diagnosis only, day þ10. CMV viremia diagnosed day þ27, initially treated with ganciclovir, recurrent viremia (ganciclovir resistant) resolved with foscarnet. Bacterial sinusitis, diagnosed day þ41. { Panel reactive antibody positive at class I (25%) with specificity for A30 and A31 (not donor directed). # aGVHD of the skin, diagnosed on day þ20, maximal grade II.
** Bacteremia with Streptococcus viridians day þ1 and Staphylococcus epidermidis day þ32. yy Failing immune suppressive therapy, no matched sibling donor. zz CD3 chimerism was followed monthly and was 100% on day þ147. xx aGVHD of the skin, diagnosed on day þ22, maximal grade II.
Conditioning and graft-versus-host disease prophylaxis
Patients with Fanconi anemia (FA) received fludarabine 25 mg/m 2 on days À10 to À5 and cyclophosphamide 10 mg/kg on days À5 to À2. All other patients received fludarabine 25 mg/m 2 on days À6 to À1, cyclophosphamide 50 mg/kg on day À2, and 200 cGy total body irradiation on day À1. All patients received cyclosporine and mycophenolate mofetil for graft-versus-host disease (GVHD) prophylaxis beginning on day À2. Cyclosporine was adjusted to maintain an infusional or trough level of 200 to 300 ng/mL and was continued through at least day þ180. Mycophenolate mofetil was administered at 15 mg/kg/dose (p.o. or i.v.) 3 times daily through at least day þ45.
Clinical Endpoints
The primary objective of this study was to determine the feasibility of administering the 6 doses of alefacept to multiply transfused pediatric patients with NMD undergoing HSCT. In addition, infusional reactions, grade 2 or greater regimen-related toxicities (RRT; through day þ42, according to Bearman criteria), graft failure (primary and secondary), graft loss, acute and chronic GVHD (using National Institutes of Health consensus criteria), and unexpected serious adverse events were captured.
Immune Monitoring
Longitudinal flow cytometric analyses included the enumeration of NK cells (CD3 Testing was performed on samples from days À40, À26, À6, and 0 using a minimum of 100,000 events. TruCount beads (Becton Dickinson) were used to generate cell counts.
Retrospective Control Subjects
To provide clinical and laboratory data for comparison, we obtained data on 23 patients who did not participate in this trial and received unrelated (marrow or cord blood) HSCT at CHOA for marrow failure (acquired or inherited) after 2000. This was approved by the CHOA Institutional Review Board.
Statistical Analysis
Statistical analyses were performed using Prism version 5 for Mac OS X (GraphPad Software, La Jolla, CA). Paired t-tests were used to calculate P values comparing baseline immunologic values with those after all doses of alefacept were given and before transplant conditioning.
RESULTS
Patient Characteristics and Clinical Outcomes
Three patients were enrolled. Patient 1 was a 2-year-old girl with dyskeratosis congenita (DKC) and marrow failure requiring 17 erythrocyte and 42 platelet transfusions before undergoing 5/6 unrelated cord blood transplant with a cell dose of 11.9 Â 10 7 TNCs/kg (Table 1) . She tolerated her alefacept infusions without complication. Post-HSCT she developed grade 2 RRT consisting of stomatitis. Peripheral blood donor chimerism (CD3 and CD33) was 100% on day þ30 post-transplant and on all subsequent analyses (Table 1 ; last analysis at 2 years post-transplant). On day þ27 she was diagnosed with acute GVHD (aGVHD) of the skin and gastrointestinal tract (maximal grade III) that responded to systemic steroid treatment. She developed severe chronic GVHD (cGVHD) with involvement of the gastrointestinal tract and heart (recurrent pericardial effusions, possibly serositis), which was treated with steroids and drainage due to cardiac tamponade. Both of these cGVHD sequelae ultimately resolved. She had several infections post-HSCT, including pulmonary aspergillosus, recurrent cytomegalovirus viremia, and bacterial sinusitis, all of which responded to treatment. She is currently off immune suppression and without GVHD approximately 3.5 years post-transplant. She has developed chronic restrictive pulmonary disease, requiring nasal cannula oxygen, and hepatic fibrosis, both attributed to DKC. Patient 2 was a 10-year-old boy with FA and marrow failure requiring 16 erythrocyte and 12 platelet transfusions before undergoing 5/6 unrelated cord blood transplant with cell dose of 4.6 Â 10 7 TNCs/kg (Table 1) . His panel reactive antibody screen was positive at class I (25%) before HSCT with specificity for A30 and A31, neither of which were donor-directed. He tolerated his alefacept infusions without complication. Post-HSCT he developed grade 2 RRT (stomatitis). Sorted (CD3 and CD33) peripheral blood chimerism studies demonstrated 100% donor chimerism on day þ30 post-transplant and on all subsequent analyses (Table 1 ; last analysis at 13 months post-transplant). He developed aGVHD of the skin on day þ20 that was maximally grade II and that responded to systemic steroids. The patient developed moderate cGVHD with involvement of (Table 1) . She tolerated her alefacept infusions without complication. There was no RRT. She had 85% CD3 and 100% CD33 donor chimerism on day þ30; subsequent analyses showed 100% CD3 chimerism by day þ147 with the last analysis at 1 year post-transplant (Table 1 ; CD3 and CD33 both 100% donor at that time). The patient developed aGVHD of the skin on day þ22 that was maximally grade II and that resolved with systemic steroids. She did not develop cGVHD or have any infections post-HSCT. She is currently approximately 2.5 years post-transplant and without symptoms of GVHD off immune suppression.
The retrospective control group comprised 23 patients who received unrelated marrow or cord blood (single or double) transplants for a variety of diseases, including SAA, FA, DKC, Diamond-Blackfan anemia, and ShwachmanDiamond syndrome. Four (17.4%) patients suffered rejection.
Post-Transplant Leukocyte Reconstitution
As shown in Figure 1 , the leukocyte reconstitution (WBC, absolute neutrophil count [ANC], absolute monocyte count [AMC], and absolute lymphocyte count [ALC]) of the 3 patients was similar to that of the retrospective control subjects. Neutrophil engraftment (first-day ANC > 500 cells/ mL for 3 consecutive days) occurred on days þ13, þ17, and þ21 in the 3 trial patients and at a median of 21 days (AE1.2 days) in the control subjects. An AMC > 200 cells/mL was achieved in the trial patients on days þ12, þ16, and þ15 and at a median of þ18.8 days (AE1.0 days) in the control subjects. An ALC > 1000 cells/mL was achieved in the trial patients by days þ17, þ60, and þ435; in historical control subjects, ALC > 1000 cells/mL was achieved by 20%, 47%, 80%, and 100% by days þ60, þ100, and þ180 and 1 year, respectively.
Pharmacodynamic Monitoring of the Pretransplant Impact of Alefacept on T Cells and NK Cells
Flow cytometry was performed on peripheral blood samples during the alefacept treatment preconditioning phase as follows: baseline (day À40, before the first dose of alefacept), during alefacept (day À26, before the third dose of alefacept), and after the final dose of alefacept but before the start of conditioning (on day À6 or À10 depending on the conditioning regimen used) and before transplant (day 0). Hematologic and immune monitoring included the enumeration of WBC, ANC, AMC, NK cell count, total T and B lymphocyte counts, and the proportion and absolute number of CD4 and CD8 T cell subsets.
Patients 1 and 3 demonstrated no statistically significant change in the WBC, ANC, ALC, AMC, T lymphocyte, and B lymphocyte counts or their relative proportions during the alefacept treatment (Figure 1 , P > .1 for all analyses when data combined). Patient 2 did demonstrate a decline in the number of WBC, granulocytes, and T and B lymphocytes with stable monocyte counts during this time period. Of note, although this patient had testing for FA at initial diagnosis that was inconclusive (and therefore received SAA-type therapy for bone marrow failure before HSCT), repeat testing before transplant confirmed a diagnosis of FA. During treatment for aplastic anemia, patient 2 had received antithymocyte globulin (horse and rabbit) and cyclosporine, which were given 6 to 12 months before receiving alefacept. In addition, he was receiving granulocyte-colony stimulating factor and low-dose prednisone (<.2 mg/kg/day) daily during alefacept preconditioning.
To determine the impact of alefacept preconditioning on CD4 þ and CD8 þ cells, the CD4 þ and CD8 þ T naive, Tem, Tcm, and Temra were divided into CD2 hi (putative alefacept target peripheral blood samples using flow cytometry. Samples were drawn at baseline (day À40, before the first dose of alefacept), during alefacept (day À26, before the third dose of alefacept), after the final dose of alefacept but before the start of conditioning (on day À6 or À10 depending on the conditioning regimen used), and before transplant (day 0). cells) and CD2 lo populations (putative nontargets, Figure 2A and B) [37] . As shown in Figure 2, Figure 2C ), with the largest decline observed in patient 1. The absolute number of the CD56 hi NK subset likewise decreased in all 3 patients, and the frequency of these cells decreased in patients 1 and 3.
DISCUSSION
This is the first study to report the use of alefacept, a recombinant LFA-3/IgG1 fusion protein targeting CD2, as a component of the conditioning regimen in patients undergoing HSCT. We report the clinical outcomes and immune effects of alefacept preconditioning in our first 3 patients before the drug was removed from production by the drug company in 2011. Alefacept was well tolerated in this study, with no infusional reactions or drug-related toxicity. Although all 3 patients were at heightened risk for graft rejection by virtue of their NMDs, their extensive transfusion history, the use of mismatched donors (2 being 5/6 cord blood units), and the use of a reduced-intensity conditioning regimen, all 3 achieved sustained, full-donor engraftment [15] [16] [17] [19] [20] [21] [22] [23] 38] .
In this series we found that alefacept decreased memory T cell subsets, predominantly in CD8 þ T cells, had no effect on naive T cells, and led to a decrease in NK cells. All 3 patients had a notable decline in the percentage of CD2 hi CD8 þ memory cell subsets, which was statistically significant for Tcm and Tem. This corresponded to an individual decline in the number of CD2 hi CD8 þ Tem and Temra cells in all 3
patients. Consistent with the expression of CD2 on NK cells, we also observed a decrease in both the absolute numbers and proportions of these cells in all 3 patients. Animal models indicate that in the setting of MHCmatched transplantation, rejection induced by transfusionrelated alloimmunization is mediated primarily by T cells [39] . Given the challenges to demonstrating donor-directed cellular immunity clinically, we did not attempt to assess it. Therefore, we cannot ascertain the extent to which pretransplant transfusions may have posed a barrier to engraftment in our 3 patients. Although a much larger study would be needed to accurately gauge alefacept's efficacy, that all 3 patients achieved full donor engraftment nevertheless raises the possibility that it might promote engraftment, especially because the incidence of rejection was 17.4% in our control group. Also, even higher incidences have been observed in registry studies of unrelated HSCT for FA, DKC, and other forms of marrow failure [10, 17, 40] .
The immune effects of alefacept have been described primarily in psoriasis and after solid organ transplant [30, 36, [41] [42] [43] , although its use has recently been reported in pediatric patients with newly diagnosed type 1 diabetes mellitus [44] . In these populations, alefacept was found to predominantly decrease CD4 þ and CD8 þ memory T cells with only a modest depletion of NK cells [41, 42] . Although NK cells are uniformly CD2 high [45] [46] [47] and therefore should be targeted by alefacept, previous studies have not demonstrated any significant effect [41, 42] . However, unlike in psoriasis, solid organ transplant, and type 1 diabetes, our study used a higher dose of alefacept and shorter total course. Although our data do not specifically address this, it is possible that this higher alefacept dose was able to more efficiently target NK cells than the lower doses used in previous studies. This represents an important area for future investigation.
Of note, the degree of memory T cell depletion was also lower in this study compared with previous results in psoriasis patients, where alefacept led to a steep decline in CD4 þ and CD8 þ memory T cell counts (CD45RO þ ) [30, 36] . The decrease in memory T cells continued through the 12 weeks of therapy in the psoriasis patients; however, most of the decline occurred in the first 6 weeks of therapy with counts dropping by greater than 50% [30, 36] . Given that depletion of memory T cells by alefacept has been shown to rely on ADCC, which is prominently mediated by NK cells [46] , it is possible that the current regimen favored depletion of NK cells. Also, with fewer of these cells available, ADCC of memory T cell populations was less effective. Although depletion of NK cells may have beneficial effects on engraftment, it is important to note that NK cells have also been shown to be integral to tumor and viral immunity post-HSCT [48] and that there have been selected reports of malignancy in patients receiving long-term alefacept for autoimmune indications [43, 49] . Two limitations of our study beyond its small size are that we did not perform pharmacokinetic testing and did not rigorously assess immune reconstitution. Together, these limitations make it difficult to determine to what extent if any that alefacept may have hindered immune reconstitution. Further studies with this drug, or other agents targeting CD2, would benefit from a detailed analysis of pharmacokinetics, a determination of the impact of pretransplant treatment on post-transplant reconstitution of NK and T cells subsets, and functional immune studies (including response to vaccines) in treated patients.
In addition to alefacept, other agents, such as antibodies directed against LFA-1 (efalizumab) [50, 51] or CD2 (siplizumab) [51] [52] [53] [54] , have been studied with the goal of depleting memory T cells. However, unlike alefacept, these drugs do not selectively deplete memory T cells and may have more serious off-target effects on protective immunity to new pathogens [55] . Unfortunately, in 2011 production of alefacept was halted based on fiscal, not clinical, factors. This decision has had a significant negative impact on multiple fields in addition to HSCT, including systemic autoimmune disease, solid organ transplant, and type 1 diabetes [42] [43] [44] 56] . The results of the current case series add to the strong rationale for reviving alefacept or similar agents, which deserve expanded analysis for their utility in multiple immune-mediated diseases. This case series also suggests that further studies using higher dosing schedules of alefacept may impact NK cells in addition to memory T cells and that an escalating dose of alefacept may alter the cell types targeted to favor either memory T cells or NK cells. This may make a significant clinical impact on patients undergoing HSCT for NMDs who are at high risk for rejection by both innate and adaptive immune mechanisms.
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INTRODUCTION
Treatment with ABL tyrosine kinase inhibitors (TKI) has become the cornerstone of chronic myeloid leukemia (CML) therapy in recent years. Chronic phase CML patients achieving deep molecular responses (MR) on long-term TKI therapy may be thought of as having a "functional" cure and withholding TKI treatment in patients with continuous deep responses is currently under intensive investigation [1, 2] .
Nevertheless, allogeneic (Allo) stem cell transplantation (SCT) is still the only modality with proven efficacy in advanced phase cases and is a valid option in TKI-resistant cases. Absence of BCR-ABL transcripts after SCT with sensitive methods (ie, achieving PCR negativity) correlates with long-term disease-free survival, whereas re-emergence of BCR-ABL transcripts has been shown to predict disease relapse and is, therefore, used to trigger therapeutic interventions, such as the addition of a TKI or donor lymphocyte infusion [3] [4] [5] [6] . With the widespread use of PCR to detect BCR-ABL transcripts, it has become clear that achieving PCR negativity is not synonymous with molecular complete response but rather depends on the sensitivity of the method used and technical variables, such as the RNA quality in each specific sample [7] . Real-time quantitative PCR (RT-qPCR) is the most commonly used method for follow-up of CML 
